Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study.

Takahiro ItoKazuhiro YamamotoFuminori OhsawaIkuo OtsukaAkitoyo HishimotoIchiro SoraMidori HiraiIkuko Yano

Published in: Journal of pharmaceutical health care and sciences (2018)

Special attentions should be paid to the onset of extrapyramidal symptoms in schizophrenia patients identified as CYP2D6 IM undergoing risperidone therapy.

Keyphrases

bipolar disorder
end stage renal disease
ejection fraction
newly diagnosed
stem cells
patient reported outcomes
mesenchymal stem cells
cell therapy
chemotherapy induced